MYC and cancer: Although one medicine for a driver oncogene activated alternative signaling pathways, the combination treatment including miR-145, which affects various oncogenes, restrained the alternative signaling pathways including MAPK/ERK, PI3K/AKT, and c-Myc, which are necessary to maintain the cancer specific energy metabolism.